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Abstract
Circulating tumour DNA (ctDNA) shows promise as a minimally invasive 
biomarker with a myriad of emerging applications including early detection 
and diagnosis, monitoring of disease and treatment efficacy, and identification 
of actionable alterations to guide treatment. The potential utility of ctDNA in 
colorectal carcinoma (CRC) is of particular interest given the limitations of cur-
rent radiographic imaging and blood-based tumour markers in detecting disease 
and evaluating therapeutic benefit. While ctDNA has yet to demonstrate clinical 
utility in CRC, a growing body of research highlights the potential of these novel 
biomarkers. This chapter provides an overview of the current evidence for employ-
ing ctDNA in CRC as well as previewing the future directions that these exciting 
technologies may take.
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1. Introduction
Ongoing research in oncology aims to generate patient-directed treatment 
options, targeting each individual’s specific cancer molecular profile with thera-
pies most likely to initiate and maintain an effective anti-tumour response [1]. 
Currently, molecular profiling in colorectal cancer (CRC) relies on direct biopsy 
of tumour tissue. However, tissue biopsy presents a number of procedural and 
biological challenges. Firstly, it is an inherently invasive procedure, making recur-
rent sampling difficult. Secondly, results may be affected by bias owing to tumoural 
heterogeneity. Tumours are affected by factors such as genomic instability, the 
surrounding tissue microenvironment and therapeutic effects [2]. These influences 
create dynamic molecular selection and evolution, resulting in spacial and temporal 
heterogeneity, which cannot be represented by a single site tissue biopsy, particu-
larly in the case of metastatic disease [3].
Recognition of these limitations has prompted an interest in non-invasive 
circulating tumour-specific biomarkers. The concept of ‘liquid biopsy’ originally 
described the detection and analysis of circulating tumour cells (CTC) in blood, 
with reference to tissue biopsy. More recently, it has been broadly adapted to 
describe any tumour-related constituents circulating in body fluids such as CTC, 
DNA, RNA and exomes [4]. Compared with tissue biopsies, liquid biopsies may 
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be better suited for serial surveillance, by reducing procedural time and potential 
harm. Blood sampling may also provide a more accurate representation of global 
tumoural heterogeneity, not limited to the site-specific characteristics detected 
through tissue biopsy [5]. The focus of this review will be directed towards circu-
lating tumour DNA (ctDNA) found in blood samples, which at present, of all the 
liquid biopsy approaches, has had the greatest clinical impact. CtDNA is thought 
to be released by tumour cells, containing tumour-specific genetic and epigenetic 
alterations [6]; and has been found to correlate with tumour stage, burden of 
disease and response to therapy in CRC [7].
Herein, we provide an overview of ctDNA technologies in use and highlight 
the emerging clinical applications of ctDNA in various CRC management set-
tings (Figure 1). The future directions of this rapidly advancing field will also be 
explored.
2. ctDNA methodological approaches and technical considerations
Circulating cell-free DNA (cfDNA) was first detected in 1948 by Mendel and 
Metais in the peripheral blood plasma of healthy and diseased individuals [8]. 
CfDNA levels can vary between 1 and 10 ng mL−1 in plasma and can be affected 
by physiological conditions such as exercise and acute inflammation [9]. In 1977, 
Leon et al. found that cfDNA was more elevated in cancer patients compared with 
healthy subjects, with higher levels correlating with higher burden of disease [10]. 
In 1989, Stroun et al. discovered that at least part of the plasma DNA in cancer 
patients originated specifically from cancer cells [11]. In the ensuing decades, 
knowledge and applications of tumour-derived cfDNA has rapidly evolved due to 
advances in molecular techniques, and also gave rise to the term, circulating tumour 
DNA (ctDNA).
Figure 1. 
Emerging ctDNA applications in various CRC management settings.
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A variety of tumour-specific molecular alterations may be identified by ctDNA 
including mutations, methylation variants, microsatellite alterations, copy number 
variations and structural changes [12]. Although the exact mechanisms are yet to 
be elucidated, ctDNA is thought to be released into the blood stream via biological 
processes such as apoptosis, necrosis, inefficient phagocytosis and active secretion 
[13, 14]. CtDNA has a short half-life of up to a few hours and accounts for gener-
ally only a small fraction of cfDNA, although concentration can vary widely from 
<0.01 to 90% [12]. The biological and tumoural determinants underlying ctDNA 
variations both between and within individuals are incompletely understood, but 
are likely affected by tumour burden, treatment response, circulatory elements, 
circadian rhythm, cellular turnover and clearance mechanisms [12, 15]. Somatic 
variants may also be found in healthy individuals, mostly commonly associated 
with clonal haematopoiesis [5]. Such variability, coupled with the often-low allele 
frequency of the molecular aberration of interest, demand sensitive and robust 
detection methods. As we interpret the results of ctDNA studies and consider their 
clinical relevance, it is prudent to reflect on these biological variables.
2.1 Pre-analytic considerations
Numerous inherent challenges have affected the development of ctDNA pre-
analytic and analytic methods. These include variable fragmentation, low abun-
dance in plasma or serum volumes, tumour heterogeneity, and low stability as a 
result of the aforementioned biological factors [16].
To minimise sample degradation and optimise stability, a number of pre-
analytical steps need to be carefully planned. Although there are currently no 
standardised methodology guidelines on ctDNA collection, storage and processing, 
the typical workflow is illustrated in Figure 2:
2.2 Detection methods
A variety of methods for detecting and characterising ctDNA have been 
reported. These can be broadly categorised as targeted and non-targeted 
approaches. Differing performance characteristics, strengths and disadvantages 
may also facilitate complementary roles of these approaches in molecular analysis. 
Table 1 lists examples of described methods. Applying any of these approaches in 
Figure 2. 
Pre-analytical components in ctDNA analysis. (1) Collection of blood samples (usually 5–10 mL) via 
phlebotomy. Currently, there is no guidance on the comparative impact of the source of blood draw (for 
example, peripheral venepuncture or intravascular ports) on ctDNA analysis [5]; (2) samples should be 
collected in tubes containing anticoagulants compatible with polymerase chain reaction methods, such as 
ethylenediaminetetraacetic acid (EDTA) [9]; (3) centrifugation of blood to separate cells should be performed 
promptly. The exact optimal time to centrifugation is not known and may depend on storage conditions and 
the presence of stabilising agents [16]. Current evidence suggests that plasma is preferred to serum samples, as 
in the latter case, cfDNA released during white blood cell lysis may lead to a dilutional effect [9]. (4) Processed 
plasma is then generally stored frozen, often in aliquots; (5) CfDNA is extracted using commercially available 
kits. There are multiple DNA purification strategies and modifications, which may variably impact on DNA 
yield and purity [5].
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routine clinical practice in a credentialed laboratory would require considerable 
scaling up, standardisation, and optimisation of methodological efficiency and 
accuracy, while minimising cost [5].
Earlier approaches such as Sanger sequencing and conventional polymerase 
chain reaction (PCR)-based methods have limited sensitivity for ctDNA detection, 
particularly for rare alterations [6]. A number of digital PCR-based approaches 
were subsequently developed, capable of improved limits of detection (up to 
0.001%), low frequency allele detection and nucleic acid quantitation. Commonly 
used digital PCR methods for ctDNA detection include BEAMing (beads, emulsion, 
amplification and magnetics) and droplet digital PCR (ddPCR). BEAMing which 
combines beads in emulsion and flow cytometry, was first described in 2003 [17] 
and facilitated serial tracking of mutant allele fractions in patients with CRC [9, 18]. 
This method and its variations are now widely applied in ctDNA analysis. DdPCR 
involves the massive partitioning of nucleic acids into thousands of droplets to 
enable highly sensitive and precise detection and quantitation of small concentra-
tions of DNA [19, 20].
Next generation sequencing (NGS) or massively parallel sequencing are broad 
terms describing a range of high throughput methods capable of the simultaneous 
analysis of thousands to millions of DNA molecules, and also encompasses both 
targeted and non-targeted approaches. Targeted sequencing platforms such as 
safe sequencing system (Safe-SeqS) [21] and tagged-amplicon deep sequencing 
(TAm-Seq) [22] have the advantage of improved multiplex capability and evaluat-
ing a larger number of loci simultaneously in the genomic areas of interest [15]. 
However, targeted PCR-based or NGS methodologies mostly rely on prior knowl-
edge of molecular changes and cannot identify variants located in areas that are not 
analysed.
In contrast, non-targeted genome or exome-wide sequencing allows discovery 
of de novo alterations as well as detection of structural changes including rearrange-
ments, gene fusions and copy number alterations [23]. These may be advantageous 
in patients who do not have accessible tumour tissue for biopsy. Several techniques 
have been described and used in the ctDNA setting. The personalised analysis of 
rearranged ends (PARE) method uses paired-end sequencing, and was utilised 
in a proof-of-principle study to identify unselected genome-wide chromosomal 
alterations characteristic of tumour DNA in cfDNA in patients with CRC and 
Technique types Technique Application
PCR-based [26–28] ARMS-PCR
Mutant allele-specific 
PCR
Bi-PAP
Known point mutations
Digital PCR [18–20, 29] BEAMing
DdPCR
Known point mutations
Targeted sequencing  
[21, 22, 30]
Safe-SeqS
TAm-Seq
CAPP-Seq
Point mutation
Structural changes in specific gene 
regions
WGS and WES [24, 31, 32] PARE
Digital karyotyping
Copy number variations
Structural rearrangements
PCR, polymerase-chain reaction; ARMS, amplification-refraction mutation system; Bi-PAP, bidirectional 
pyrophosphorolysis-activated polymerisation; BEAMing, beads, emulsion, amplification and magnetics; ddPCR, 
droplet digital PCR; Safe-Seq, safe-sequencing system; TAm-Seq, tagged-amplicon deep sequencing; WGS, whole-
genome sequencing; WES, whole-exome sequencing; PARE, personalised analysis of rearranged ends.
Table 1. 
Methods of ctDNA detection.
5Current Utility and Future Applications of ctDNA in Colorectal Cancer
DOI: http://dx.doi.org/10.5772/intechopen.82316
breast cancer, including copy number changes and rearrangements [24]. Another 
group demonstrated the feasibility and utility of exome-wide sequencing in ctDNA 
to identify mutations associated with acquired therapeutic resistance in a small 
cohort of patients with advanced cancer [25]. Current limitations of non-targeted 
approaches include lower sensitivity and relatively prohibitive costs impeding 
routine clinical implementation [24]. Furthermore, due to the relatively large 
amount of resulting sequencing data, substantial bioinformatic expertise and filters 
are required to decipher somatic tumoural alterations from the structural variants 
commonly seen in germline DNA to avoid false positives [15].
3. CtDNA in screening
Five-year survival for CRC patients is highly dependent on the timing of disease 
detection and tumour stage. CRC screening can achieve early disease detection and 
treatment, including that of pre-malignant dysplastic lesions, and has been shown 
to improve CRC-related mortality. However, 60–70% of patients are diagnosed at 
mid- to late stage CRC despite recent advances in screening methods [33]. Screening 
approaches used to test asymptomatic people for a presence of unsuspected disease, 
which have proven efficacy in CRC include endoscopic visualisation and faecal 
occult blood tests (FOBT). The former is invasive and expensive with associated 
morbidity, thus affecting patient compliance and acceptance. FOBT measure 
the presence of haemoglobin in faeces and can be categorised into guaiac-based 
(gFOBT) and the newer haemoglobin-antibody-based faecal immunochemical test 
(FIT). FIT is used more commonly in current practice and has largely superseded 
gFOBT, due to its superior sensitivity for colorectal bleeding, improved analytical 
characteristics and it is also less likely to be affected by dietary and medication 
factors [34–37]. In addition, FIT has better acceptance and participation which 
improves population participation [38]. In a meta-analysis of 19 studies, FIT was 
found to have high accuracy and specificity, and moderately high sensitivity, 
although substantial heterogeneity was noted across studies [39].
This prompted the development of faecal-based tests targeting genetic and epi-
genetic alterations. Cologuard is the first commercially-approved faecal test which 
combines several technologies including molecular assays for aberrant NDRG4 and 
BMP3 methylation, β-actin (a reference gene for human DNA quantity), and KRAS 
mutations; and a haemoglobin immunoassay [40]. The haemoglobin component 
of the Cologuard test contributes to 80% of the cancer detection in the algorithm. 
A large randomised clinical trial comparing Cologuard and FIT screening showed 
that the sensitivity of Cologuard was superior to that of FIT in the detection of CRC 
and precancerous lesions [40]. However, the higher cost of Cologuard and its lower 
specificity compared with FIT has limited its adaptation as a screening tool [33].
CtDNA analysis may offer a more convenient screening approach compared 
with faecal-based tests. The malignant transformation pathway, from adenoma to 
carcinoma, is driven by mutations such as APC, KRAS and TP53 [41]. However, 
somatic mutational profiles are highly variable between patients. For example, 
KRAS and BRAF V600E are seen in approximately 40 and 7% of patients with 
CRC respectively [42]. To date, the vast majority of cancer patients evaluated 
with mutation-based blood plasma assays have advanced-stage disease. A chal-
lenge in early stage disease is the often-minute fraction of ctDNA present in the 
total circulating DNA—may be as low as <0.01%—which may be below the limit 
of detection assays [18]. A study which enrolled 170 patients with positive FOBT 
investigated differences in KRAS mutation levels in plasma and tissue samples [43]. 
The rate of KRAS mutations in plasma (3%) was found to be lower compared with 
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that observed in matched adenocarcinoma and high-grade intra-epithelial neoplasia 
tissues (45%) [43]. Although this is a small study, the results suggest that either 
this particular assay is not sufficiently sensitive, or that ctDNA was found at low or 
undetectable levels in the population tested.
The detection of epigenetic alterations characterised by aberrant DNA meth-
ylations is an alternative approach to mutational ctDNA analysis. Aberrant DNA 
methylation leads to transcription silencing of tumour suppressor genes, occurs 
early in CRC carcinogenesis, and may be more commonly seen and consistent in 
cancer patients compared with somatic mutations. Indeed, DNA methylation pro-
files in plasma have been used in biomarker development to identify emergence of 
early CRC by several groups [44]. One of the methylated promotors that has gained 
a lot of interest is the Septin 9 gene promoter. Methylation in the Septin 9 promoter 
demonstrated high sensitivity in preclinical studies and a small clinical cohort  
[45, 46], however a large prospective screening study demonstrated a sensitivity 
profile of only 48% [47]. In addition, the sensitivity to detect advanced adenomas 
was low (11%) [47]. Despite this, in 2016, the FDA approved the use of the Epi pro-
Colon, a plasma-derived Septin 9 methylation assay, for the screening of CRC. This 
decision occurred in the setting of encouraging results from a meta-analysis 
comparing the pooled sensitivity of methylated Septin 9 with FOBT as a screening 
tool [48], and the improved sensitivity and specificity results of a modified ver-
sion of the Epi proColon assay (2.0 version) [49, 50]. Recently, promising results 
have been reported in the utilisation of two methylation markers in the screening 
context—branched-chain amino acid transaminase 1 (BCAT1) and ikaros family zinc 
finger protein 1 (IKZF1)—where methylation of either gene identified close to 70% 
of CRC with specificity of 92% [51, 52].
To date, ctDNA is yet to demonstrate clinical utility in the CRC screening 
setting. Challenges lie in minimising false positive readings, whilst developing 
a test sensitive enough to detect small amounts of ctDNA. For example, normal 
physiological ageing is associated with the development of somatic mutations 
in the absence of malignant disease, and false positive readings may also be seen 
in patients with chronic inflammatory disease. False positive results can lead to 
unnecessary follow-up procedures and anxiety. Studies examining a large number 
of healthy control individuals will be essential to evaluate the specificity of poten-
tial screening assays. Yet another challenge with ctDNA-based screening is the 
identification of the underlying tissue of origin. Because the same gene mutations 
drive multiple tumour types, ctDNA tests based on genomic analysis alone gener-
ally cannot identify the anatomical location of the primary tumour.
4. CtDNA in detection of residual disease in early stage CRC
Although surgical resection can cure a high percentage of patients with CRC, 
tumour recurrence occurs in approximately 30–50% of all patients who undergo 
curative resection. The majority of these recurrences take place during the first 2 years 
after surgery and 90% recur within 5 years [53, 54]. Recommendation for adjuvant 
cytotoxic therapy is based on clinicopathological risk, although it may not be neces-
sary in many patients and toxicity is substantial. Thus, biomarkers that would aid in 
identifying patients at high risk of recurrence and who would benefit from adjuvant 
therapies is of utmost importance. Carcinoembryonic antigen (CEA), a blood protein-
based tumour marker, is currently used for monitoring CRC treatment and can also be 
detected at elevated levels in pancreatic, gastric, lung and breast cancers, as well as a 
number of benign conditions. Whilst CEA is upregulated in the majority of advanced 
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CRC, the sensitivity for recurrence detection has been shown to be unacceptably low, 
approximately 30% [55, 56], supporting the need for alternative markers.
It is well known that in CRC, there is high genomic concordance between the 
primary tumour and its metastases [57]. Therefore, a promising strategy to detect 
minimal residual disease or even relapsed disease, could be to use ctDNA to track and 
quantify key genomic aberrations (APC, KRAS, BRAF and TP53), which are recognised 
as playing a role in early CRC, and may persist in metastatic disease [18, 58]. Several 
studies have shown that peri-operative ctDNA detection is associated with higher rate 
of recurrence and in some cases, poorer overall survival; albeit with varying detection 
methodology, sensitivity and specificity [59–63]. Additionally, the aforementioned 
methylation markers BCAT1 and IKZF1 have also shown promise in a study of patients 
with resected stage I–IV CRC, where post-operative positivity for BCAT1/IKZF1 meth-
ylation was more sensitive (68%) for recurrence detection than CEA (32%, p < 0.05) 
and its odds of recurrence given a positive test (14.4, 95% CI: 5–39) was twice that of 
CEA (6.9, 95% CI: 2–22) [64]. However, they fail to detect advanced adenomas despite 
their frequent presence in cancer and adenoma tissue [65]. It would be reasonable to 
speculate that the release of any DNA from neoplasia seems to be a function of progres-
sion along the oncogenesis pathway and it is not a simple reflection of whether or not 
the change is present in tissue.
These preliminary studies support the need for large prospective trials evaluat-
ing pre- and post-operative ctDNA-based biomarkers to help predict recurrence 
and evaluate prognosis. However, it is not yet known whether ctDNA represents 
the molecular diversity of disease or whether only selective clones (for example, 
highly apoptotic clones) are secreted into the bloodstream. Furthermore, it is yet to 
be established whether early detection of recurrence can indeed improve survival 
outcomes, if treatment is followed soon after.
5. CtDNA in metastatic CRC (mCRC)
For the majority of patients with mCRC, the mainstay of treatment consists of 
palliative-intent systemic therapy with median overall survival (OS) approaching 
24 months. Three classes of cytotoxic agents (fluoropyrimidine, irinotecan and 
oxaliplatin) and two classes of molecularly-targeted agents (monoclonal antibodies 
targeting vascular endothelial growth factor [VEGF], and the epidermal growth 
factor receptor [EGFR]) are currently approved for use in mCRC, although the 
optimal sequencing and scheduling of these treatments are debated. To optimise 
their therapeutic ratio and minimise toxicity, effective and accurate means of 
assessing treatment response are needed. In the following section, we summarise 
the evidence on the use of ctDNA in mCRC management. These include prognos-
tication, monitoring tumour burden and predicting treatment efficacy, guiding 
targeted treatment selection, and detecting anti-EGFR therapy resistance.
5.1 CtDNA in mCRC: prognostic value and monitoring tumour burden
The association between the presence or high levels of ctDNA and adverse 
survival outcomes in mCRC has been demonstrated in several studies [66–69]. 
For example, in a landmark study, Bettegowda et al. observed a steady decrease in 
2-year survival rate as ctDNA concentration increased [69]. Moreover, a systematic 
review exploring the prognostic role of ctDNA in CRC (mostly mCRC) found that 
most studies, although not all, demonstrated a negative correlation between ctDNA 
and disease-free survival and OS [70].
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Another application for ctDNA that has been explored in mCRC is correlat-
ing longitudinal dynamics during systemic therapy with prediction of treatment 
response and tumour burden [71]. Currently, anatomical radiographic imag-
ing—particularly computed tomography (CT)—is the chief modality to evaluate 
therapeutic benefit in mCRC. However, limitations include cost, operator- and 
reader-dependence, challenges in standardisation and radiographic lag behind 
clinical changes. Furthermore, changes in tumour size which form the basis of 
response measurement on CT does not account for changes in tumour density or 
morphology that may result from response to molecularly targeted agents com-
monly used in mCRC. CEA is also used in mCRC disease monitoring, usually 
in-between or in addition to radiology assessments. However, CEA is elevated in 
only approximately 70–80% of patients with mCRC and has limited sensitivity and 
specificity in detecting disease progression or treatment response [72].
A study of 53 mCRC patients undergoing standard first-line chemotherapy, 
found that significant decline in ctDNA levels using Safe-SeqS prior to cycle two 
chemotherapy was associated with objective radiological response at 8–10 weeks 
(p = 0.016) [73]. This study also found a trend between ctDNA reduction and 
improved progression-free survival. The more recent PLACOL study in 82 patients 
receiving chemotherapy for mCRC echoed these findings [7]. PLACOL utilised 
picodroplet-digital PCR assays based on either genomic or hypermethylation 
alterations. The investigators found that the baseline ctDNA concentration was 
prognostic for OS, and that early and deep ctDNA reductions were associated with 
improved objective response rate and longer survival (p < 0.001) [7]. Another 
recent study using digital PCR found methylation changes over time correlated with 
tumoural response in patients with mCRC [74].
These studies suggest that early changes in ctDNA during systemic therapy may 
be predictive for treatment efficacy and prognostic for survival outcomes, thus sug-
gesting a role for serial ctDNA monitoring during palliative treatment with systemic 
therapy. Indeed, with the advantages of a short half-life reflecting immediate-term 
changes [18] and high tumour-related specificity, ctDNA monitoring may be 
complementary to radiological assessments and blood biomarkers currently in 
use. In clinical circumstances where radiological assessments are indeterminate 
or ambiguous, such as the lack of measurable disease by imaging criteria or the 
presence of mixed response, ctDNA dynamics may be of particular value; although 
ctDNA may not always correspond to imaging findings [75]. Equally, it is also pru-
dent to acknowledge that no current evidence supports the strategy of biomarker-
monitoring of palliative therapy and that earlier adaptive treatments will augment 
survival or quality of life.
5.2 CtDNA in mCRC: genotyping to guide targeted treatment selection
It is now standard of care for patients with mCRC to undergo molecular profil-
ing on their tumour tissue in order to determine BRAF V600E and Rat sarcoma 
(RAS, particularly exon 2–4 KRAS) gene mutational status. This informs clinical 
decision-making regarding benefit from anti-EGFR therapy. The advantageous role 
of genotyping with ctDNA has already been established in the field of advanced 
non-small cell lung cancer. Circulating genetic aberrations of EGFR (for example, 
exon 19 deletions or exon 21 (L858R) substitution mutations) are now being used 
in standard practice, as a companion tool, to identify eligible patients for treat-
ment with erlotinib. This technology was approved by the US Food and Drug 
Administration in 2016 for this indication [76].
In mCRC, a meta-analysis of 21 studies on the diagnostic performance of 
ctDNA-based KRAS gene detection found overall high pooled specificity (96%) 
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and moderate sensitivity (67%) [77]. Not surprisingly, heterogeneity was noted to 
be high probably owing to varying molecular techniques, tumour stage and study 
designs [77]. Although a number of KRAS ctDNA assays have demonstrated high 
agreement (91–93%) with tumour tissue KRAS testing and are available for com-
mercial use [78, 79]; at present, tumour tissue testing remains the gold standard 
to establish KRAS mutational status. Given the appreciable discordance rate with 
tumour tissue genotyping, it is recommended that a negative ctDNA result should 
trigger tumour tissue variant analysis [5]. As will be discussed under Section 6, 
ctDNA assays in mCRC may also been utilised to select predictive immune-related 
biomarkers for immunotherapy selection.
5.3 CtDNA in mCRC: genotyping to monitor for targeted treatment response 
and resistance
The role of genomic alterations and their evolution in both the development and 
progression of CRC have culminated in the realisation that serial genotyping of the 
primary tumour, and its secondaries, is ideally required if we want to succeed in 
personalising patient care with precision [80]. Unfortunately, patients with mCRC 
who do not harbour a somatic RAS mutation pre-treatment, will typically develop 
acquired resistance to anti-EGFR therapy in a matter of months after initially show-
ing response. There is a battery of pre-clinical and clinical evidence which points to 
the acquisition of molecular mechanisms of resistance associated with aberrations 
in the RAS-MEK-mitogen-activated protein kinases (MAPK), pathway [2, 42, 81, 82].
Longitudinal ctDNA analysis can be used in this setting with high diagnostic 
precision to detect both primary resistance and early molecular changes that may 
confer acquired resistance. Several translational studies have successfully employed 
ctDNA to illustrate and verify the emergence of RAS mutations as a mechanism of 
acquired resistance to anti-EGFR therapy.
In a phase II trial of anti-EGFR antibody, panitumumab in mCRC, serial pro-
spective plasma analysis detected more emergent RAS mutations than serial tissue 
biopsies, suggesting that the former may be more comprehensive in evaluating 
global tumoural heterogeneity [83]. In a small retrospective study of 10 mCRC 
patients who developed resistance to anti-EGFR therapy (cetuximab or panitu-
mumab) in combination with chemotherapy, Misale et al. demonstrated that the 
onset of the emerging KRAS mutations was detected in serum ctDNA analysis as 
early as 10 months prior to radiological reporting of disease progression [2]. In 
this study, ctDNA analysis was also explored in a separate cohort of patients who 
were receiving chemotherapy alone (control group). No acquired KRAS mutations 
were identifiable at disease progression [2]. In the same year, Diaz et al. also dem-
onstrated the feasibility of using serum ctDNA to identify emerging resistance to 
panitumumab in a prospective cohort of 28 patients [81]. Thirty-eight percent of 
patients whose tumours were initially KRAS wild type developed detectable KRAS 
mutations in their sera, three of whom developed multiple different KRAS muta-
tions. These were detected approximately 5 months before radiological progression 
[81]. Another study subsequently made the intriguing observation that KRAS 
clones can fluctuate under the selective pressure of anti-EGFR therapy implying 
that there may be a role for ‘pulsing’ or re-challenging with anti-EGFR therapy [84].
Furthermore, in a prospective study of 108 patients, treated in the third line 
setting with cetuximab and irinotecan, Spindler et al. investigated the quantitative 
correlation between plasma cfDNA with tumour-specific plasma mutant KRAS 
levels [85]. This study revealed that (i) the majority of KRAS mutations that were 
detected in tumours were also found in the plasma, (ii) there was a strong correla-
tion between cfDNA and plasma mutant KRAS levels, and (iii) high levels of plasma 
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mutant KRAS were associated with 0% disease control rate [85]. More recently, 
a large retrospective exploratory analysis used BEAMing technology to identify 
KRAS, PIK3CA and BRAF mutations in the plasma ctDNA of 503 patients who 
enrolled in the CORRECT trial of regorafenib, a multi-kinase inhibitor in refrac-
tory mCRC [66]. Tumour-associated KRAS mutations were readily detected with 
BEAMing of plasma DNA and were identified in 48% of patients who had previ-
ously received anti-EGFR therapy and whose archival tumour tissues were KRAS 
wild type [66].
Beyond KRAS mutations and amplifications, acquired genetic aberrations in 
other genes have been found to potentially lead to anti-EGFR therapy resistance, 
albeit in smaller subsets of patients. For example, emerging EGFR extracellular 
domain (ECD) mutations which lead to impaired antibody binding were found to 
be a resistance mechanism to anti-EGFR therapy in approximately 20% of patients. 
Interestingly, these mutations tend to arise later than RAS mutations during ther-
apy, and patients with EGFR ECD mutations had greater and more durable response 
to anti-EGFR therapy than patients with RAS mutations [86]. Interestingly, a phase 
I trial of a third generation EGFR-targeting agent that binds multiple regions of 
the EGFR ECD demonstrated efficacy in patients with EGFR ECD mutations and 
acquired resistance to prior EGFR blockade [87]. Other genomic alterations linked 
to acquired resistance to EGFR blockade include MET and ERBB2 amplifications 
[88, 89] and mutations in NRAS, BRAF and PIK3CA [6]. ERBB2 amplification was 
found in the plasma in four out of eight RAS wild type patients who derived no 
clinical benefit from anti-EGFR treatment, suggesting that it may also be a source of 
primary resistance [84].
Another innovative study provided proof-of-principle that parallel analysis 
of patient-derived xenografts and ctDNA allowed the identification of resistance 
mechanisms to a pan-tropomyosin-related kinase (TRK) inhibitor in mCRC, with 
validation in preclinical models [90]. In interpreting these translational findings, 
it is important to note that typically, multiple complex molecular abnormalities 
emerge rather than a singular clone and an overlap exists between abnormalities 
associated with primary and secondary resistance [6].
CtDNA genotyping has now paved the way for prospective clinical trials 
which aim to evaluate a range of targeted agents in mCRC and their resistance 
mechanisms. However, significant knowledge gaps exist in the field, including 
lack of standardisation of ctDNA techniques, clinical relevance of minority clones 
detected (for example, no threshold for KRAS allele frequency has been established 
to predict anti-EGFR therapy resistance) and it remains to be proven that chang-
ing treatment strategy according to ctDNA findings improves patient outcomes 
[6]. Challenges notwithstanding, it is foreseeable that in the near future, ctDNA 
genotyping may be used longitudinally to (i) identify RAS wild type patients with 
mCRC who may be suitable for anti-EGFR antibodies, (ii) dynamically assess 
treatment response, (iii) identify patients who are developing acquired resistance, 
(iv) delineate resistance mechanisms to therapy, and (v) discover new druggable 
targets.
6. Future directions
Despite growing enthusiasm, ctDNA in CRC remains largely unavailable for 
clinical application outside of the trial setting. Recently, there has been a surge of 
research to further investigate the utility of more sensitive and accurate technolo-
gies for ctDNA detection and analysis, and to further elucidate its clinical imple-
mentation and significance in the various settings of CRC management.
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6.1 Advancing ctDNA detection accuracy
Improved sensitivity techniques with the use of targeted-sequencing methods have 
been developed by several groups [9, 91]. For example, Lanman et al. validated the 
analytical and clinical use of a novel, ultra-high specific, digital sequencing technique 
(Guardant360) consisting of 54 clinically actionable cancer genes [91]. In 165 con-
secutively matched plasma and tumour tissue samples from patients with advanced 
cancer, this study demonstrated significantly improved sensitivity for Guardant360 in 
the plasma-derived cfDNA compared to that of tumour tissue. It also demonstrated the 
clinical success rate of the assay in 1000 consecutive plasma samples in the clinic (assay 
failure rate of 0.02%) due to its ability to eliminate false positives [91].
Other investigators have combined the use of DNA fragment sequencing by 
using molecular barcodes with relevant bioinformatics filtering steps to enhance 
sensitivity and specificity [30, 69, 92, 93]. In a study using cfDNA from mCRC 
patients, Mansukhani et al. showed that false positive mutation calls could be 
reduced by 98.6% when incorporating novel molecular barcodes for error correc-
tion and by applying custom solution hybrid capture enrichment [93].
6.2 Detecting aberrant DNA methylation
Several studies have explored the use of DNA methylation markers that may 
have a role in CRC screening and diagnosis, and which in some cases may have 
similar sensitivity and specificity to the aforementioned Septin 9 methylation assay 
(for example, APC, MGMT, RASSF2A, Wif-1, ALX4, NEUROG1) [94–99]. More 
compelling is the evidence suggesting that the use of a combination of DNA meth-
ylation markers—a multigene methylation signature—may enhance sensitivity 
and specificity compared with single biomarker detection [94, 96]. Such an assay, 
utilising the methylation of both BCAT1 and IKZF1, has shown promising results in 
this setting as previously discussed [51, 52, 64, 100].
6.3 Using CTC, extracellular vesicles, and microRNA as adjuncts biomarkers
This chapter has highlighted the recognisable potential for a paradigm shift 
with the use of ctDNA for the molecular diagnosis and monitoring of CRC, as well 
as its multiple drawbacks when used in isolation. Notably, ctDNA is largely unable 
to evaluate biomarkers other than genomic aberrations. An alternative approach 
is the use of tools such as CTC, extracellular vesicles, and circulating microRNAs 
(miRNA), in conjunction to ctDNA, to overcome these limitations.
6.3.1 CTC
A significant limitation of utilising CTC as a biomarker in CRC, particularly in 
early disease, is that they are difficult to detect in the blood due to a large propor-
tion being captured in the liver prior to entering the general systemic circulation 
[101–103]. Furthermore, there have been a number of heterogenous studies, 
systematic reviews and meta-analyses which demonstrate conflicting results for 
the role of CTC as a prognostic biomarker [104–106]. This makes interpretation 
very challenging. Nonetheless, it is worth noting that detectable ctDNA and CTC as 
biomarkers are distinct entities and, in isolation, neither can be regarded as optimal 
surrogates of the multiclonal malignant state in an individual CRC patient. As dis-
cussed earlier, ctDNA is likely to be released by apoptotic or necrotic tumour cells, 
rather than highly proliferative cells, within a multiclonal tumour [103]. However, 
we do not know whether all clones have the same apoptotic potential, and therefore 
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detectable ctDNA levels in CRC patients do not always correspond to the ability to 
detect CTC [102, 107]. As such, it would be worth exploring the concomitant use of 
both of these biomarkers in a liquid biopsy.
6.3.2 Extracellular vesicles
The clinical utility for these small, membrane-bound cell fragments, which are 
also thought to originate from apoptotic, necrotic or proliferating tumour cells, has 
also recently been considered [108]. Depending on their size and content, they fall 
under the categories of exosomes, microvesicles, and apoptotic bodies. In particular, 
tumour-derived exosomes are constitutively formed and released from tumour cells 
and can be found in the peripheral circulation, other body fluids and interstitial 
spaces. They can contain concentrated forms of RNA, miRNA, long non-coding 
RNA, nucleic acids, protein and lipids, but only very small amounts of double-
stranded DNA [109]. As such, exosome-derived nucleic acids from the serum of CRC 
patients may be used to identify genetic aberrations from the tumour that are not 
detectable by ctDNA, and therefore can be used in a complementary fashion with 
other biomarkers. To date, there is no published data that has alluded to their clinical 
application in CRC. Intriguingly, exosomes have recently been shown to have roles in 
cell-cell signalling which may affect tumour growth and development [110].
6.3.3 miRNA
The role of circulating, exosome-free miRNAs as potential diagnostic and prognos-
tic biomarkers in CRC has been extensively investigated over the past 5 years [111–116]. 
However, owing to extensive heterogeneity between several studies, it has been 
difficult to gauge their clinical worth in terms of sensitivity and specificity, which has 
often been described as ‘modest’. Encouragingly, recent studies have suggested that by 
using miRNA panels or signatures, the predictive accuracy of these assays can be sig-
nificantly enhanced [117, 118]. In mCRC, only a few studies have addressed the role of 
circulating miRNAs as predictive biomarkers to systemic therapy [119]. Conceptually, 
miRNA assays could be used in conjunction with ctDNA, or with the aforementioned 
biomarkers, to facilitate accurate read-outs for improved sensitivity and specificity.
6.4 Detecting microsatellite phenotype
The use of immune-checkpoint inhibitors has drastically changed the thera-
peutic landscape for several solid tumours, including a mCRC subset that harbours 
mutations in DNA mismatch repair (MMR) genes (for example, mutations in 
MLH1, MSH2, MSH6, PMS2, or MLH1 promoter hypermethylation) [120]. On a 
molecular level, impaired DNA MMR can lead to genomic hypermutability, includ-
ing uncontrolled expansion or contraction in DNA microsatellite repeats, termed 
microsatellite instability (MSI); and the consequent development of malignant 
neoplasms which have an MSI-high (MSI-H) phenotype. The MSI-H phenotype is 
present in approximately 15% of all primary CRC and may occur as a result of either 
inherited (hereditary non-polyposis colon cancer or lynch syndrome) or sporadic 
abnormalities. It is now common for institutions to screen for this in tumour tissue, 
either by immunohistochemistry for deficient MMR (dMMR) or PCR for MSI [121]. 
The identification of the MSI-H phenotype in CRC patients has important prognos-
tic and therapeutic implications, both in the adjuvant and advanced settings when 
considering conventional chemotherapeutic and targeted agents.
More recently, a small phase II clinical trial using pembrolizumab, an anti-
programmed cell death protein 1 (PD1) monoclonal antibody in dMMR mCRC 
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patients, demonstrated high rates of objective response (40%) and progression-free 
survival, while no responses were seen in proficient MMR patients [122]. Similarly, 
a phase II study of anti-PD1 antibody, nivolumab in dMMR/MSI-H mCRC showed 
31% objective response rate and 69% disease control rate (12 weeks or longer) [123]. 
In addition to these encouraging results, multiple trials using anti-PD1 agents, 
with or without other targeted therapies are ongoing (for example, NCT02460198, 
NCT02563002, NCT02060188), and it is expected that immunotherapy will rapidly 
become standard of care in dMMR/MSI-H mCRC.
In this setting, liquid biopsy might be useful in providing a potentially faster, cost-
efficient, and safer approach compared to tumour biopsy sampling in patients with 
suspected MSI-H tumours. Therefore, such assays need to be optimised for routine 
use in the future. The novel ctDNA techniques described earlier in this chapter could 
be adapted to identify dMMR CRC in several ways, such as change in microsatellite 
length, loss of heterozygosity, mutations, or hypermethylation of MMR-related genes 
[124]. However, similar drawbacks regarding their sensitivity and specificity apply 
in this setting [125]. To overcome these limitations, several groups have developed 
enrichment techniques which are able to enhance the presence of altered microsatel-
lites with enrichment probes and detect alterations at very low allele frequencies [126].
Moreover, ctDNA in the setting of immunotherapy can also be used (i) as a 
predictive marker to identify tumour mutational burden or specific response 
mutations (for example, PTEN loss or activating beta-catenin mutations), (ii) to 
monitor treatment response or resistance in conjunction with radiological imaging, 
and (iii) to identify neoepitopes and epigenetic or transcriptomic markers [124]; 
although the data for such techniques are preliminary at this stage.
6.5 Detecting ctDNA in other body fluids
This chapter has predominantly focused on the utility of ctDNA in the periph-
eral blood. Multiple studies have also demonstrated the presence of tumour-derived 
nucleic acids in other body compartments, such as the urine, stool, saliva, cere-
brospinal fluid, pleural fluid, and bronchial washings [40, 127–129]. Of course, 
topography of the primary tumour, and of any disseminated lesions, will have a 
significant effect on the concentration of ctDNA in different body fluids.
In a small study, Fujii et al. demonstrated the utility of detecting KRAS mutations 
in the urine of mCRC patients who were undergoing systemic treatment. Both NGS 
and enrichment PCR were used to detect KRAS in the urine, plasma and archival 
tumour tissue [128]. The results not only suggested good concordance between ctDNA 
in the urine and mutant KRAS in the tumour, but also demonstrated that ctDNA 
trends in the urine reflected the tumour dynamics in the plasma. As such, this may also 
represent an alternative approach to monitoring for therapeutic response or resistance.
7. Conclusion
The data generated from basic research, retrospective clinical studies, and 
limited prospective studies all support the potential role of ctDNA as a biomarker 
for early disease, minimal residual disease, recurrence, response to therapy, and 
emerging drug resistance mechanisms in the management of CRC. Nevertheless, 
multiple challenges need to be overcome before this promising technology can be 
adopted into routine clinical practice.
Firstly, a crucial question is whether the genomic aberrations detected in ctDNA 
actually drive tumour progression. It is also still unknown whether ctDNA will 
ever be able to mirror the heterogeneity or molecular subclones of CRC in a given 
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Clinical trial identifier Study title
Curatively treated CRC (recurrence surveillance and prognostication)
NCT02842203 Use of ctDNA for Monitoring of Stage III Colorectal Cancer
NCT02842203 Circulating Tumour DNA Analysis to Optimise Treatment for 
Patients With Colorectal Cancer (IMPROVE)
NCT03416478 The Implication of ctDNA in the Recurrence Surveillance of Stage 
II and III Colorectal Cancer
NCT03312374 ctDNA as a Prognostic Marker for Postoperative Relapse in Early 
and Intermediate Stage Colorectal Cancer
NCT02997241 Colon Cancer Treatment Decisions and Recurrence Predicting 
(CCTDRP)
NCT03189576 Measuring Molecular Residual Disease in Colorectal Cancer After 
Primary Surgery and Resection of Metastases
NCT03038217 Investigation of the Value of ctDNA in Diagnosis, Treatment, and 
Surveillance of Surgically Resectable Colorectal Cancer
NCT03615170 Application of Circulating Tumour DNA Test in the Diagnosis and 
Treatment of Patients With Advanced Rectal Cancer
mCRC—monitoring during chemotherapy
NCT02872779 Correlation Between Circulating Tumour Markers Early Variations 
and Clinical Response in First Line Treatment of Metastatic 
Colorectal Cancer (COCA-MACS)
NCT02948985 Evaluation of CTCs Combined With Tumour Marker Detection of 
Efficacy of Chemotherapy in mCRC
mCRC—RAS testing
NCT02502656 RAS Mutation Testing in the Circulating Blood of Patients With 
Metastatic Colorectal Cancer (RASANC)
NCT03227926 Rechallenge With Panitumumab Driven by RAS Dynamic of 
Resistance (CHRONOS)
NCT03259009 RAS Mutations in ctDNA and Anti-EGFR reINTROduction in 
mCRC (RASINTRO) (RASINTRO)
mCRC—MSI testing
NCT03561350 Detect Microsatellite Instability Status in Blood Sample of 
Advanced Colorectal Cancer Patients by Next-Generation 
Sequencing
NCT03594448 Detection of MSI in Circulating Tumour DNA of Colorectal 
Carcinoma Patients
Large multi-disease observational studies
NCT03517332 Circulating Tumour DNA Exposure in Peripheral Blood
NCT02838836 Tumour Cell and DNA Detection in the Blood, Urine and Bone 
Marrow of Patients With Solid Cancers
NCT03027401 Clinical Sequencing of Cancer and Tissue Repository: 
OncoGenomics
Other
NCT03546569 Tumour Cells, Tumour DNA and Immunological Response in 
Colonic Stent Placement (CISMO)
NCT03284684 Kinetics of Perioperative Circulating DNA in Cancer Surgery 
(Periop ctDNA)
NCT02579278 Circulating Tumour DNA (ctDNA) Rectal Cancer and the 
Relationship to Extramural Venous Invasion (ctDNA Trial)
Table 2. 
Currently recruiting and upcoming clinical trials assessing ctDNA in CRC (http://clinicaltrials.gov).
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patient. Further clarity is also needed regarding intra-patient variability in ctDNA 
levels, the dynamics of ctDNA release and ctDNA clearance. Such knowledge will 
inform the design of future studies, particularly regarding the optimal timing of 
ctDNA assessment relevant to the appropriate therapeutic intervention.
Secondly, to determine the true value of ctDNA analysis in guiding decision-mak-
ing, carefully designed and well-controlled prospective trials are needed to address 
clinically relevant questions for various settings. An important question, for example, 
is how to utilise ctDNA detection as a biomarker of minimal residual disease after 
resection of a stage I–III CRC. Can we use this biomarker to make decisions about the 
necessity, type and duration of adjuvant therapy and guide follow-up or surveillance 
scheduling? Another question is how to use ctDNA to monitor for the emergence of 
molecular resistance and can we use this approach to inform us about timely adapta-
tion of further treatment lines? Table 2 lists selected currently recruiting and upcom-
ing clinical trials assessing the utility of ctDNA in various settings in CRC.
Importantly, pre-analytical considerations, ctDNA detection techniques, 
and interpretation of results need to be standardised. On review of the current 
literature, it will be obvious to the reader that there is a high level of heterogene-
ity amongst various techniques. Consequently, results that are obtained from 
one study cannot be interpreted in the same way and applied to other techniques. 
Standardisation will ensure that there is consensus regarding the sensitivity and 
specificity of utilised techniques and that there are established cut-off levels, for 
each clinical setting. Finally, it is important to acknowledge that the use of promis-
ing novel technologies will have cost implications which may hinder their rapid 
entry into routine clinical practice.
Glossary
Allele 
frequency
The relative frequency of a gene variant in a specimen, expressed as a percentage or fraction
CfDNA Cell-free DNA. DNA fragments found circulating in body fluids, including plasma or 
serum. CfDNA may come from a variety of sources including tumour cells
CtDNA Circulating-tumour DNA. A proportion of cfDNA that is tumour-derived
Liquid 
biopsy
Sampling and analysis of tumour-based material (e.g. CTC, ctDNA, RNA, exosomes) from 
body fluids such as blood, urine and pleural fluid
NGS Next generation sequencing (NGS) or massively parallel sequencing are broad terms 
describing a range of high throughput methods capable of the simultaneous analysis of 
thousands to millions of DNA molecules
PCR Polymerase chain reaction. A laboratory technique used to make many copies 
(amplification) of a specific DNA sequence of interest
Pre-
analytical
The pre-analysis phase in the laboratory testing process and may include sample collection, 
handling, processing, transport and storage. These factors can affect the subsequent 
analysis outcomes
Clinical 
utility
The ability of an intervention or test to demonstrate benefit in patient care compared to not 
using the intervention or test
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